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Accepted 28 December 2011AbstractObjective: The aim of this case-control study was to investigate whether the vitamin D receptor (VDR) 1a promoter gene polymorphisms are
associated with susceptibility to polycystic ovary syndrome (PCOS).
Methods: Women with PCOS and a control group, all aged 18e45 years, were enrolled. Genotypes of two functional single nucleotide poly-
morphisms (SNPs), the 1521 bp (G/C) and 1012 bp (A/G), located on the 1a promoter of the VDR gene were determined by using direct
sequencing. Serum 25-hydroxyvitamin D levels were measured by ELISA.
Results: Two functional SNPs in the 1a promoter region of the VDR gene were in complete linkage disequilibrium. The genotype distributions of
these two polymorphisms in the PCOS group were not significantly different from those of the control group. Further subgroup analyses
according to body mass index also revealed no significant differences in the genotype distribution in the PCOS group. Significantly lower
serum 25-hydroxyvitamin D levels were observed in the heterozygous 1521CG/1012GA haplotype of both groups. Metformin treatment was
only effective to increase serum 25-hydroxyvitamin D levels in PCOS patients carrying the homozygous 1521G/1012A haplotype.
Conclusion: These results suggest that the VDR 1a promoter polymorphisms may not be associated with the risk for PCOS, but are associated
with serum 25-hydroxyvitamin D levels. Metformin treatment will be beneficial to PCOS patients without the VDR 1a promoter variant in
Taiwanese population.
Copyright  2012, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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Polycystic ovary syndrome (PCOS) is a common endocrine
disease in reproductive women with a complex hormonal
disturbance that affects the menstrual cycle and leads to
metabolic consequences in later life [1]. PCOS is associated* Corresponding author. Department of Obstetrics and Gynecology, National
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Road, Tainan 70428, Taiwan.
E-mail address: mhwu68@mail.ncku.edu.tw (M.-H. Wu).
1028-4559/$ - see front matter Copyright  2012, Taiwan Association of Obstetri
http://dx.doi.org/10.1016/j.tjog.2012.09.011with obesity, insulin resistance, and increased risk of type 2
diabetes mellitus, dyslipidemia, cardiovascular disease, and
endometrial carcinoma. It is known that vitamin D is involved
in the pathogenesis of type 2 diabetes because it affects insulin
metabolism [2]. Vitamin D needs to be converted to its active
form and activates vitamin D receptor (VDR) to regulate target
gene expression. Serum concentration of 25-hydroxyvitamin
D is considered to be the most reliable indicator of clinical
vitamin D status, and a circulating 25-hydroxyvitamin D level
<80 nM (32 mg/L) is defined as vitamin D deficiency [3].
Vitamin D is also thought to play a role in the pathogenesis ofcs & Gynecology. Published by Elsevier Taiwan LLC. All rights reserved.
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correlated with body mass index (BMI), indices of insulin
resistance, and leptin levels in PCOS women [4]. In addition,
PCOS women with features of metabolic syndrome have lower
serum 25-hydroxyvitamin D levels than PCOS women without
these features [5]. However, the relationship between PCOS
and vitamin D deficiency is inconsistent from these studies.
Although low 25-hydroxyvitamin D levels are associated with
increased risk for various disorders, such as cardiovascular
disease, diabetes, and metabolic syndrome, the therapeutic
benefits of vitamin D supplementation require further explo-
ration [6]. In obese PCOS women, vitamin D analogue treat-
ment was found to increase the first phase of insulin secretion
significantly and to improve the lipid profile [7].
PCOS is characterized by anovulation, hyperandrogenism,
and polycystic ovarian morphology. Ultrasound examination,
especially 3D ultrasonography, may help in the evaluation of
ovarian morphology and the diagnosis of PCOS [8]. Menstrual
abnormality is also an important characteristic in the diagnosis
of PCOS. Laparoscopic ovarian drilling or gonadotropin
stimulation is recommended as a second-line therapy for
clomiphene citrate-resistant anovulatory PCOS women under
metformin treatment. Our previous study found that this
surgical procedure may help to improve endocrine profiles and
intraovarian stromal flow in patient with PCOS [9]. However,
it has the risk of decreased ovarian reserve and adhesion
formation. Some PCOS patients can normalize their menstrual
cycles after calcium plus vitamin D supplementation [10].
Vitamin D replacement treatment may also improve metabolic
parameters and menstrual frequency in PCOS women [11].
The combination of calciumevitamin D and metformin in the
infertility treatment of PCOS patients demonstrated a better
response in dominant follicular development and possible
improvement of menstrual irregularities than either drug alone
[12]. However, as these findings were based on a small scale of
study (small sample size), further studies using larger sample
sizes should be warranted.
Although familial aggregation indicates a genetic suscep-
tibility to PCOS, the genetic etiology of PCOS remains
unknown. There are large interindividual differences in the
signs and symptoms among women with PCOS. Interaction of
multiple genetic factors with environmental, particularly
nutritional factors, might contribute to the heterogeneity of
clinical and biochemical features in PCOS [13]. There are also
ethnic and racial variations in the prevalence of PCOS and its
symptoms. Some subtle DNA sequence variations (single
nucleotide polymorphisms, SNPs) may occur more frequently
in the population of PCOS, which may change the
formation of protein complexes and the biologic effects. Our
previous result showed different inflammatory responses
among PCOS patients with insulin receptor substrate-2 poly-
morphisms in the Taiwanese population [14]. Interleukin-6
may be considered as an early low-grade chronic inflamma-
tory marker among PCOS patients with the insulin receptor
substrate-2 Gly1057Asp polymorphism. IL-6 was significantly
elevated in PCOS women, especially in the insulin receptor
substrate-2 homozygous Asp population, and significantlydecreased after metformin treatment in this homozygous Asp
variant.
Mahmoudi suggests that the VDR polymorphisms may be
associated with phenotype development and insulin resistance
in PCOS women [15]. In an evolutionary comparison study,
VDR 1a promoter is highly conserved among mammals. There
are two functional SNPs in the 1a promoter region of the VDR
gene [16], the 1521 bp (G/C) and 1012 bp (A/G), located
within a GATA site with human specificity [17]. In this study,
we hypothesized that these two functional SNPs may influence
VDR expression and might then be associated with suscepti-
bility to the phenotypes of PCOS. We used candidate gene
polymorphism investigation to find the correlation and effects
of VDR 1a promoter SNPs in PCOS patients in a Taiwanese
population. This study may facilitate the establishment of
a domestic gene polymorphism databank via SNP study to
provide more detailed genetic information for PCOS, and to
understand the functional consequences of these variations.
Materials and methodsPatientsFrom November 1, 2007 to January 31, 2009, a hospital-
based study was conducted to investigate the association
between VDR 1a promoter SNPs and PCOS. A study group of
188 women with PCOS were enrolled, along with 143 women
without any evidence of PCOS as a control group; the women
of both groups were aged 18e45 years. The patients were
observed for routine gynecological examination at National
Cheng Kung University Hospital, Tainan, Taiwan. The study
was approved by the hospital’s institutional ethics committee
and informed consent was obtained from each patient.
Patients with PCOS were diagnosed according to the 2003
Rotterdam ESHRE/ASRM criteria [18]. The diagnosis was
based on the presence of at least two of the three following
criteria: oligomenorrhea and/or amenorrhea; clinical and/or
biochemical evidence of hyperandrogenism; and polycystic
ovaries determined by ultrasonography with exclusion of other
etiologies. The control group of women without PCOS had
regular menstrual cycles, and no evidence of hyper-
androgenism or polycystic ovaries.
Clinical, biochemical, and ultrasonographic evaluation was
performed in each participant. Biochemical laboratory
parameters at baseline and 3-month metformin administration
were evaluated after an overnight fast and a 75-g 2-hour oral
glucose tolerance test. Biochemical assessment consisted of
complete hormonal, including serum follicle stimulating
hormone, luteinizing hormone, thyroid-stimulating hormone,
prolactin, estradiol, 17-OH-progesterone, total testosterone,
and sex-hormone binding globulin; metabolic evaluation
included evaluation of lipid, glucose, and insulin levels.
Insulin resistance was evaluated using the homeostasis model
analysis [fasting glucose (mg/dL)  fasting insulin (mU/mL)/
405], the quantitative insulin-sensitivity check index {1/
[log(fasting insulin) þ log(fasting glucose)]}, and the fasting
glucose-to-insulin ratio (A/I). When women with PCOS had
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tablets with the same regimen (3 tablets daily) for 12 weeks.GenotypingA 10 mL whole blood sample was taken from each
participant for genotyping. Genomic DNA was extracted
from whole blood using the GeneMark extraction Kit
(GeneMark Technology Co., Ltd., Tainan, Taiwan) according
to the manufacturer’s instructions. Genotyping of the two
promoter SNPs [rs7139166 (1521 C﹥G), rs4516035 (-1012
T﹥C)] of the human VDR gene were performed by using
direct sequencing. PCR reaction was carried out using
primers forward 50-TGC AGA GAA TGT CCC AAG GT-30
and reverse 50-GTC CTG CCA GTC TGA TGG AT-30 for
the 1521 C﹥G polymorphism, and primers forward 50-AGC
AGA TTT GCT GGG CTC TA-30 and reverse 50-TGC TTC
CCT TGA CTG TGT GA-30 for the 1012 T﹥C poly-
morphism. The PCR reactions were performed in 96-well
microtiter plates and the sequencing reactions were per-
formed using the ABI BigDye Terminator reagents (Applied
Biosystems, Foster City, CA, USA). The PCR products were
sent to the Nucleic Acid Sequencing Center of National
Cheng Kung University for sequencing using the ABI 3100
DNA sequencer (Applied Biosystems). The sequence data
were analyzed by using the PolyPhred software (v5.04) [19].
The genotypes were assigned to the participants indepen-
dently by two individuals blinded to the participant
information.Enzyme immunoassay for the quantitative determination
of serum 25-hydroxyvitamin D levelsThe commercial 25-hydroxy Vitamin D enzyme immuno-
assay kit (Immunodiagnostic Systems Inc., Fountain Hills, AZ,
USA) was used for quantification of the serum levels of 25-
hydroxyvitamin D according to the manufacture’s protocol.
The diluted samples with biotin-labeled 25-hydroxyvitamin D
were incubated with a highly specific sheep 25-hydroxyvitamin
D antibody for 2 hours at room temperature. Horseradish
peroxidase-labeled avidin was added to bind selectively to
complexed biotin. After color was developed using a chromo-
genic substrate, the absorbance of each well at 450 nm
(reference 650 nm) was read in a plate reader. A standard
calibration curve of signals was used to calculate the 25-
hydroxyvitamin D concentration of unknown patient samples.
The sensitivity of 25-hydroxyvitamin D assay was 5 nM, and
intra- and interassay coefficients of variance were 5.3% and
4.6%, respectively.Statistical analysisContinuous results are expressed as mean  SEM. A two-
sample t test was used to evaluate the clinical variables
between patients and controls. One-way analysis of variance
was used to evaluate the parameters among three groups. A
paired t test was used to evaluate the 25-hydroxyvitamin Dchanges before and after metformin therapy in PCOS patients.
Pearson’s c2 tests were used to test for the difference of allelic
and genotypic frequencies of VDR 1a promoter SNPs between
groups. Logistic regression analysis was performed to evaluate
an association between specific VDR 1a promoter alleles and
their susceptibility to PCOS. Odds ratios (ORs) and 95%
confidence interval (95% CI) from the logistic regression
model were used to estimate the magnitude of the association
between the VDR 1a promoter genotype and PCOS. Statistical
analyses were performed using the SPSS program (Version
15.0, SPSS Inc., Chicago, IL, USA). A p value <0.05 was
considered statistically significant.ResultsClinical and biochemical characteristics of the study
populationThe PCOS patients had significantly higher body weight
(61.62  1.06 kg) and BMI (24.17  0.39 kg/m2) than the
control women (56.48  0.87 kg for body weight;
22.06  0.32 kg/m2 for BMI). Additionally, the levels of
luteinizing hormone and testosterone were significantly higher
in the PCOS group than in the control group. The PCOS
patients had significantly elevated levels of fasting insulin,
2 hour glucose, and 2 hour insulin during the OGTT (fasting
insulin: 8.94  0.63 mU/mL; 2 hour glucose:
112.06  4.65 mg/dL; 2 hour insulin: 61.87  4.65 mU/mL)
compared with the control participants (fasting insulin:
6.41  1.15 mU/mL; 2 hour glucose: 94.75  2.73 mg/dL;
2 hour insulin: 26.69  1.90 mU/mL; Table 1).The frequencies of VDR promoter polymorphisms
Two polymorphisms in the 1a promoter region of the VDR
gene, 1521 G/C and 1012 A/G, were genotyped
successfully in both 188 PCOS women and 143 control
women. A summary of the distributions of the genotypes and
the allelic frequencies of the VDR promoter polymorphisms
is presented in Table 2. These two adjacent SNPs, the
1521 bp (G/C) and 1012 bp (A/G), of the human VDR gene
promoter, were in complete linkage disequilibrium (r2 ¼ 1).
The homozygous genotype frequencies for 1521GG/1012AA
in normal control and PCOS groups were 91.6% and 96.3%,
respectively, while the heterozygous 1521CG/1012GA
genotype frequencies in normal control and PCOS groups
were 8.4% and 3.7%, respectively. The frequencies of the
homozygous 1521G/1012A genotype were slightly increased
in the PCOS group (OR ¼ 2.37; 95% CI ¼ 0.91e6.18;
p ¼ 0.071) as compared with the control group (Table 2).
When the PCOS women were further classified into over-
weight/obese (BMI  24 kg/m2) or lean groups (BMI < 24
kg/m2), it was found that the genotypic distribution of the
VDR 1a promoter SNPs between these two PCOS groups was
similar ( p ¼ 1.000; Table 2).
Table 1
Descriptive characteristics of the study participants.
Control group PCOS group p PCOS group
with BMI <24
PCOS group with
BMI 24
p
Participants (n) 143 188 111 75
Age (y) 31.83  0.48 28.43  0.38 <0.0001* 28.05  0.49 28.97  0.62 <0.0001**
Body weight (kg) 56.48  0.87 61.62  1.06 0.0002* 52.52  0.59 75.08  1.44 <0.0001**
Body height (cm) 159.93  0.47 159.50  0.38 0.4758 159.40  0.47 159.66  0.65 0.7351
BMI (kg/m2) 22.06  0.32 24.17  0.39 <0.0001* 20.66  0.21 29.37  0.46 <0.0001**
Waist circumference (cm) 79.82  1.79 83.40  1.10 0.1247 75.60  0.93 92.72  1.31 <0.0001**
Systolic blood pressure (mmHg) 114.03  1.23 118.34  1.09 0.0105* 112.60  1.26 126.32  1.46 <0.0001**
Diastolic blood pressure (mmHg) 69.44  1.10 70.45  0.85 0.4671 66.30  0.99 76.22  1.19 <0.0001**
Total cholesterol (mg/dL) 179.46  3.96 179.97  2.85 0.9247 174.80  3.73 186.84  4.32 0.0916
Total triglyceride (mg/dL) 82.61  5.12 102.06  4.47 0.0161* 84.26  5.01 125.70  7.05 <0.0001**
HDL-C (mg/dL) 58.55  2.48 55.378  1.15 0.1919 59.95  1.60 49.42  1.29 <0.0001**
LDL-C (mg/dL) 107.75  4.19 105.64  2.41 0.6611 100.46  3.17 112.26  3.58 0.0477**
Fasting insulin (mU/mL) 6.41  1.15 8.94  0.63 0.0423* 5.83  0.61 13.62  1.08 <0.0001**
2 h insulin (mU/mL) 26.69  1.90 61.87  4.65 <0.0001* 46.19  4.14 85.06  9.11 <0.0001**
HbA1C (%) 5.35  0.03 5.70  0.25 0.3876 5.76  0.42 5.61  0.04 0.6435
Fasting glucose (mg/dL) 86.47  0.69 87.33  0.57 0.3851 85.35  0.68 90.40  0.88 <0.0001**
2 h glucose (mg/dL) 94.75  2.73 112.06  2.39 <0.0001* 105.28  2.89 121.50  3.94 <0.0001**
HOMA index (mg/L) 1.36  0.23 1.97  0.14 0.0256* 1.24  0.13 3.07  0.25 <0.0001**
Fasting sugar/insulin 26.57  3.42 19.57  1.66 0.0415* 26.59  2.58 9.18  0.66 <0.0001**
QUICKI index (mg/L) 3.78  0.27 3.32  0.15 0.1218 3.56  0.26 2.96  0.03 0.0503
LH (mIU/mL) 6.49  0.81 8.26  0.39 0.0299* 9.31  0.57 6.77  0.48 0.0043**
FSH (mIU/mL) 6.58  0.30 6.03  0.15 0.0710 6.22  0.19 5.82  0.26 0.1424
E2 (pg/mL) 38.04  1.94 45.64  1.78 0.0086* 45.17  2.26 46.23  2.96 0.0327**
TT (nmol/L) 1.30  0.10 1.67  0.06 0.0004* 1.60  0.08 1.83  0.09 0.0002**
SHBG (nmol/L) 57.19  4.41 38.17  2.35 0.0001* 46.23  3.25 25.40  2.48 <0.0001**
17-OHP (ng/mL) 3.60  2.13 1.43  0.09 0.0891 1.37  0.10 1.52  0.16 0.2348
TSH (mU/mL) 1.92  0.12 2.04  0.09 0.4799 1.83  0.10 2.35  0.18 0.0215**
PRL (ng/mL) 12.82  0.70 12.17  0.56 0.4817 12.53  0.70 11.21  0.86 0.3330
25-hydroxyvitamin D (nmol/L) 98.47  3.70 96.42  2.99 0.6637 97.25  3.80 95.59  4.92 0.8952
*p < 0.05 by two-sample t test;** p < 0.05 compared between PCOS with BMI <24, PCOS with BMI 24, and control groups by one-way analysis of variance.
17-OHP ¼ 17-OH-progesterone; BMI ¼ body mass index; E2 ¼ estradiol; FSH ¼ follicle-stimulating hormone; HDL-C ¼ high-density lipoprotein-cholesterol;
HOMA ¼ homeostasis model analysis; LDL-C ¼ low-density lipoprotein-cholesterol; LH ¼ luteinizing hormone; PRL ¼ prolactin; QUICKI ¼ quantitative
insulin-sensitivity check index; SHBG ¼ sex-hormone binding globulin; TSH ¼ thyroid-stimulating hormone; TT ¼ total testosterone.
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The serum concentrations of 25-hydroxyvitamin D in
PCOS (n ¼ 188, 96.42  2.99 nmol/L) were lower than in the
control group (n ¼ 143, 98.47  3.70 nmol/L; Table 1),
although no statistically significant difference was found
between them. When PCOS women were divided into two
BMI subgroups, PCOS women with BMI 24 kg/m2 had
lower serum concentrations of 25-hydroxyvitamin D
(95.59  4.92 nmol/L; n ¼ 75) compared with those women
having BMI < 24 kg/m2 (97.25  3.80 nmol/L; n ¼ 111;
Table 1). We also evaluated the 25-hydroxyvitamin D
concentrations between homozygous (n ¼ 239) andTable 2
Genotypic distribution of polymorphisms in the VDR 1521 and 1012 genes among
Control group PCOS group OR (95% CI
VDR 1521/1012 n ¼ 143 n ¼ 188
Heterozygous (GC/CT) 12 (8.4%) 7 (3.7%) 1
Homozygous (CC/TT) 131 (91.6%) 181 (96.3%) 2.37 (0.91e6
The p value was calculated by logistic regression.
BMI ¼ body mass index; OR ¼ odds ratio; PCOS ¼ polycystic ovary syndrome;heterozygous (n ¼ 19) carriers of the VDR 1a promoter
SNPs and found that heterozygous participants showed
a significantly low 25-hydroxyvitamin D concentration
(63.93  6.10 nmol/L) than homozygous women
(100.03  2.40 nmol/L; p < 0.01). The findings were
consistent in both PCOS and normal control groups (Fig. 1). In
control women, 25-hydroxyvitamin D concentration was
102.43  2.39 nmol/L in homozygous individuals (n ¼ 107)
versus 63.17  6.82 nmol/L in heterozygotes (n ¼ 12;
p < 0.01). In PCOS patients, 25-hydroxyvitamin D concen-
tration was 98.08  3.03 nmol/L in homozygotes (n ¼ 132)
versus 65.22  12.51 nmol/L in heterozygous women (n ¼ 7;
p < 0.05). However, there was no significant difference inthe control group and the PCOS subgroups according to BMI.
) p PCOS group with
BMI <24
PCOS group with
BMI 24
p
n ¼ 111 n ¼ 75
4 (3.6%) 3 (4.0%)
.18) 0.071 107 (96.4%) 72 (96.0%) 1.000
VDR ¼ vitamin D receptor.
Fig. 1. The difference in serum 25-hydroxyvitamin D concentration between homozygous and heterozygous participants. *p < 0.05; **p < 0.01.
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and control women, whether homozygous or heterozygous.
There was a significant increase in the serum concentration
of 25-hydroxyvitamin D in PCOS patients after receiving
metformin therapy 3 months later (n ¼ 139; Fig. 2). The 25-
hydroxyvitamin D level in PCOS women was increased
from pretreated 96.42  2.99 nmol/L to posttreated
104.71  2.71 nmol/L ( p < 0.01) with 95% confidence
interval 9.52 to 7.062. It was interesting that there was no
improvement of 25-hydroxyvitamin D level after 3 months of
metformin therapy in heterozygous carriers of VDR 1a
promoter SNPs of PCOS patients, even with original insuffi-
cient vitamin D status (pretreated 66.00  13.68 nmol/L vs.
posttreated 64.37  7.43 nmol/L; n ¼ 7). Only homozygotes
demonstrated significantly increased 25-hydroxyvitamin D
concentration (pretreated 96.37  2.89 nmol/L vs. posttreated
105.45  2.61 nmol/L; n ¼ 132; p < 0.01), which was within
normal vitamin D status originally, after 3 months metformin
therapy.Fig. 2. The change in the serum concentration of 25-hydroxyvitamin D in PCOS
**p < 0.01.Discussion
In the present study, we found significantly low serum 25-
hydroxyvitamin D levels in heterozygous haplotype carriers of
the VDR 1a promoter region gene polymorphisms in both
PCOS and control groups. Moreover, we observed that met-
formin treatment was only effective to increase serum 25-
hydroxyvitamin D levels in PCOS patients carrying the
homozygous haplotype. However, no significant association
was found between 1521 G/C and 1012 A/G poly-
morphisms in the 1a promoter region of the VDR gene and
PCOS. Besides, we observed that these two SNPs were in
complete linkage disequilibrium (r2 ¼ 1). When we further
conducted subgroup analyses according to BMI, no significant
differences in the genotype distribution in the PCOS group
were revealed.
Our study did not find significant association between two
polymorphisms in the 1a promoter region of the VDR gene and
PCOS. One possible explanation is that a high frequencyafter receiving metformin therapy for 3 months in different SNP genotypes.
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observed in our study, which is quite different from that of
other populations. Jehan et al reported that 1521G and 1012A
are evolutionarily conserved among mammals. Homozygous
1521C/1012G haplotype frequency is found in up to 43%
Caucasians [17], and in 17.3% healthy French adolescent girls
[16]. However, this homozygous haplotype was not observed
in our study population. One the other hand, the frequency of
the heterozygous 1521CG/1012GA haplotype (57.3%) in
French adolescent girls is much higher than that of normal
controls in our study (8.4%) [16]. As there is apparent
discrepancy in the genotype frequency in different race and
ethnic groups and as many as 96% of the PCOS patients in this
series were homozygous for these VDR SNPs compared with
91% of the controls, we could speculate that the VDR 1521C/
1012G alleles are unlikely to play a major role in the devel-
opment of PCOS, but rather may have some effect in the
metformin treatment response on serum 25-hydroxyvitamin D
levels in PCOS women.
Because of the wide heterogeneity of symptoms and signs
of PCOS, which may be predisposed by multiple genetic and
environmental factors, it is hard to evaluate putative functional
correlations between VDR SNPs and PCOS. The findings re-
ported by d’Alesio et al from transfection data demonstrate
that human VDR promoter activity is 1.9-fold higher in the
homozygous 1521G/1012A haplotype compared with that of
the homozygous 1521C/1012G haplotype [16]. Moreover,
girls with the homozygous 1521C/1012G haplotype of the
VDR 1a promoter have lower 25-hydroxyvitamin D and
insulin-like growth factor-1 levels associated with shorter
adult height. However, we cannot make the same comparison
to evaluate the relationship between genotype and phenotypes
because no homozygous 1521C/1012G haplotype was
observed in our study. Despite this, our study found that
heterozygous 1521CG/1012GA women showed a significantly
lower 25-hydroxyvitamin D concentration than homozygous
1521G/1012A participants in both PCOS and normal control
groups, which is coherent with the finding of d’Alesio et al.
However, no significant difference in 25-hydroxyvitamin D
concentration was found between PCOS patients and normal
controls in either homozygous or heterozygous participants,
respectively, which might be due to the small sample size.
Vitamin D deficiency is highly prevalent and associated
with multiple metabolic risk factors in PCOS patients [20].
The use of metformin may prove beneficial in women with
PCOS in metabolic protection and ovulation induction [21].
Elevated insulin levels on a 2-hour 75-g glucose tolerance test
is an important parameter to consider in the decision to initiate
metformin therapy in women with PCOS. In our previous
ultrasound study, metformin treatment improved uterine and
ovarian blood flow in women with PCOS [22]. Although there
was no difference in the level of 25-hydroxyvitamin D
between PCOS and normal control in our present study, we
found a significant increase of serum concentration of 25-
hydroxyvitamin D in PCOS after receiving metformin
therapy for 3 months. Moreover, the 1521C/1012G homozy-
gous participants demonstrated significantly increased 25-hydroxyvitamin D concentration after metformin treatment.
The exact pathophysiological mechanisms between 25-
hydroxyvitamin D concentration and metformin therapy
remains unclear; however, previous studies have reported
a positive relationship between total serum calcium and insulin
levels as well as insulin resistance [23].
In conclusion, to the best of our knowledge, this is the first
study to report the VDR 1a promoter gene polymorphism and
metformin treatment response on serum 25-hydroxyvitamin D
levels in PCOS women. This study found significantly low
serum 25-hydroxyvitamin D levels in heterozygous haplotype
carriers of VDR gene polymorphisms in both PCOS and
control groups. Moreover, we also observed that metformin
treatment was only effective to increase serum 25-
hydroxyvitamin D levels in PCOS patients carrying the
homozygous haplotype. A potential limitation of the study is
the small sample size; therefore, we have to be cautious in
making this conclusion. Further studies using larger sample
sizes are warranted to confirm the current findings.
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